Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

250 mg/m2 is within the expected efficacy range according to Dr. Menon. If IPIX doesn’t think it might have an effect in tumors, they wouldn’t include efficacy as secondary endpoint (wasted time and money).

The slight tumor reduction in the thymoma cancer patient was due to 350 mg/m2 of K at once per week. The near disappearance of the spleen lesion in the ovarian cancer patient was due to 215 mg/m2 of K at once per week for three cycles. That’s why I think Dr. Menon decided on 250 & 350 mg/m2 in the current trial.

they are not looking for tumor shrinkage in this setup